[Skip to Content]
[Skip to Content Landing]
Citations 0
Health Agencies Update
November 20, 2002

Proteomics for Prostates

Author Affiliations

Not Available

Not Available

JAMA. 2002;288(19):2397. doi:10.1001/jama.288.19.2397-JHA20011-3-1

In a significant proof-of-concept test, the emerging technology of proteomics has shown its potential by distinguishing prostate cancer from benign prostate conditions, according to a report from the Food and Drug Administration (FDA) and the National Cancer Institute (NCI). The test, which has been in development for 4 years, analyzes protein patterns in a drop of blood, and appears to be more sensitive than the prostate-specific antigen (PSA) test, at least in men with marginally elevated PSA readings, said senior NCI Scientist Lance Liotta, MD, PhD.

First Page Preview View Large
First page PDF preview
First page PDF preview